Background
Antiplatelet agents, used as monotherapy or in combination, have a major role in preventing and managing cardiac and vascular events. In the perioperative period, the indication for antiplatelet agents is reinforced by the increased platelet activity following surgery; however, they also increase the risk of surgical bleeding.
Methods
We used systematic review that comparing several studies about perioperative antiplatelet therapy from 2010-2021 sourced from Pubmed, Medline, Cochrane and Google Scholar. Total 10 studies in this study included 3 RCT and 4 Literature Review, 2 Scientific Articles
Results
Total 547 participants included in this study reviewed based on age, type of surgery and antiplatelet therapy. All studies reported mortality, one study reported blood loss requiring transfusion P=0.08. One study reported major bleeding events but did not define major bleeding by need for transfusion or surgery P=0.94. Three studies reported ischaemic events.
Conclusion
Bleeding complications are likely to occur when Antiplatelet therapy is maintained throughout elective surgery. Although low-certainty evidence that either continuation or discontinuation of antiplatelet therapy before non-cardiac surgery may make a difference to mortality, bleeding requiring surgical intervention, or ischaemic events.
Keyword: Antiplatelet Therapy, Perioperative,
